Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Investor Presentation (July 2025)
24 slides from Jasper Therapeutics's investor presentation, Jul 7, 2025
Slide 1: Jasper Therapeutics Corporate presentation July 2025
Jasper Therapeutics Corporate presentation July 2025
Slide 2: Safe Harbor Statements
2 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safe Harbor Statements Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statem ents. All statements other than stateme
Slide 3: Briquilimab continues to demonstrate rapid onset, deep clinical response and favorable safety
3 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab continues to demonstrate rapid onset, deep clinical response and favorable safety • More than 25pt drop in UAS7 with 78% CR and 89% WC disease by week 4 with single dose ( 240mg SD & 360mg SD, n =9) • Deep redu
Slide 4: Briquilimab in Chronic Spontaneous Urticaria
Briquilimab in Chronic Spontaneous Urticaria
Slide 5: Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria
5 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Screening/Eligibility • CSU diagnosis ≥ 6 mos. • UAS7 ≥ 16 • 18+ years • H1 - antihistamine - failed • Inadequate response to omalizumab Study Operations • US Lead: Tom Casale, MD • EU Lead: Martin Metz, MD • ~30 sites in
Slide 6: BEACON Single-Dose Cohorts 240mg SD & 360mg SD
BEACON Single - Dose Cohorts 240mg SD & 360mg SD
Slide 7: 240mg SD and 360mg SD PK Concentration over Time
7 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION 240mg SD and 360mg SD PK Concentration over Time Rapid C - Max achieved around Day 5 - 8 LOQ values are imputed to 1. ALQ values are imputed to 100,000. PK values are displayed in log10 scale. 240mg SD Cohort 360mg SD Coho
Slide 8: Dose dependent reductions in serum tryptase
8 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Dose dependent reductions in serum tryptase Reduction below 1.6ug/ml in 80% (8/10) single dose 240mg & 360mg participants by week 2 Data analysis as of 3 July 2025 Weeks Serum Tryptase (ng/mL) LLOQ 0 2 4 6 8 10 12 0 1 2 4
Slide 9: 89% of patients achieving complete response following single dose
9 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION *Note: At Week 6 in the BEACON study, patients in the placebo arm were allowed rescue medications. 0 5 10 15 20 25 30 35 0 1 2 3 4 5 6 7 8 9 10 11 12 UAS7 Week Briquilimab (BEACON) Placebo (n=19) 240 mg SD (n=5) 360 mg SD
Slide 10: BEACON Multi-Dose Cohorts 240mg Q8W & 240mg/180mg Q8W
BEACON Multi - Dose Cohorts 240mg Q8W & 240mg/180mg Q8W
Slide 11: BEACON Multi-Dose Cohorts: potential issue with one drug product lot
11 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION BEACON Multi - Dose Cohorts (240mg Q8W & 240mg/180mg Q8W) 240mg Q8W & 240mg/180mg Q8W confounded by potential issue with one drug product lot • 10 of 10 patients dosed from one drug product lot (“Lot A34954”) showed no UA
Slide 12: 240mg SD UAS7 Reductions by Drug Product Lot
12 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION *Note: At Week 6 in the BEACON study, patients in the placebo arm were allowed rescue medications. 0 5 10 15 20 25 30 35 0 1 2 3 4 5 6 7 8 UAS7 Week Briquilimab (BEACON) Placebo (n=19) Lot A34954 (n=10) Other lots (n=8) 2
Slide 13: BEACON Trial Safety
pis ode BEACON TRIAL Safety
Slide 14: Briquilimab was well tolerated and demonstrated a favorable safety profile
CONFIDENTIAL BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab was well tolerated and demonstrated a favorable safety profile Pooled Placebo (N=19) n (%) Total Pooled Briquilimab (N=57) 5 n (%) 240mg D1 180mg Q8W Briquilimab (N=7) n (%) 240mg Q8W Briquilimab (N=
Slide 15: Safety observations possibly related to KIT blockade were generally low grade
15 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safety/tolerability observations possibly related to KIT blockade were generally limited to low grade events Majority resolved during repeat dosing and none resulted in discontinuations Pooled Placebo (N=19) n (%) Total P
Slide 16: Neutrophil counts generally stable with predictable reduction which resolved
16 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION 240mg SD & 360mg SD neutrophil counts generally stable with predictable reduction which subsequently resolved Mean time to resolution of 42 days, no discontinuations or dose delays due to reductions in neutrophil counts D
Slide 17: CSU Open Label Extension 180mg Q8W
CSU Open Label Extension 180mg Q8W
Slide 18: Jasper Chronic Urticaria Open Label Study (JSP-CP-014)
18 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Jasper Chronic Urticaria Open Label Study (JSP - CP - 014) Generate additional safety, efficacy and durability for both CSU and CIndU programs, at 180mg Q8W dose schedule Projected to add ~80 patients from the parent stud
Slide 19: Preliminary OLE 180mg Q8W Results
19 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Preliminary OLE 180mg Q8W Results Rapid control as early as week 1, with >25 point mean change from baseline at week 12 Data cut - off 3 July 2025
Slide 20: Briquilimab well tolerated with favorable safety profile in the OLE study
20 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Briquilimab was well tolerated and demonstrated a favorable safety profile in the OLE study Briquilimab 180mg Q8W (n=18) 16 (88) Any adverse event* 0 (0) Any serious adverse event 0 (0) Any adverse event leading to discon
Slide 21: Safety observations possibly related to KIT blockade in OLE
21 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Safety/tolerability observations possibly related to KIT blockade in OLE Briquilimab 180mg Q8W (n=18) 0 (0) Hair color change 0 (0) Skin discoloration 4 (22.2) Taste change/hypogeusia 0 (0) Neutrophil count decreased 1* (
Slide 22: BEACON Trial Summary and Next Steps
Po _—_ BEACON TRIAL Summary and Next Steps
Slide 23: Summary and Next Steps
23 BRIQUILIMAB IS AN INVESTIGATIVE DRUG AND IS NOT APPROVED FOR ANY INDICATION Potential drug product issue • Investigation of Lot A34954 ongoing, results expected in the coming weeks • Shipping fresh drug for subsequent dosing on current patients and adding 10 - 12 new patients across the two cohor
Slide 24: Jasper Therapeutics July 2025
Jasper Therapeutics NASDAQ: JSPR July 2025
Jasper Therapeutics — Investor Presentation (July 2025) on 6ix